Takeda, debt in mind, offloads 18 drugs in Asia Pacific to Celltrion for $278M

Fiercepharma | June 11, 2020

Takeda, debt in mind, offloads 18 drugs in Asia Pacific to Celltrion for $278M
Takeda has earmarked another chunk of business for divestment to help it pay down debt. The Japanese pharma is offloading 18 over-the-counter and prescription drugs marketed in the Asia-Pacific region to South Korea’s Celltrion for $278 million, it said on Thursday. The portfolio generated sales of about $140 million in the fiscal year ended in March 2019, mainly driven by DPP-4 diabetes drug Nesina and hypertension med Edarbi, Takeda said. It will continue to manufacture the products and supply them to Celltrion after the transaction closes. Takeda expects the deal to wrap up by the end of the year. As is the case with its previous deals, the sold-off drugs fall outside of Takeda’s chosen focus business areas—gastroenterology, rare diseases, plasma-derived therapies, oncology and neuroscience.

Spotlight

Modern-day research produces a vast amount of information. The cloud provides a solution for those drowning in this data deluge, and this infographic reviews how cloud-based solutions work and how they can benefit your research.

Related News

RESEARCH

XtalPi Partners with Excelra for GOSTAR to Enhance its Intelligent Digital Drug Discovery and Development platform

Excelra Knowledge Solutions Pvt Ltd | January 19, 2022

Excelra, a leading global Data & Analytics organization, announced the partnership for its Global Online Structure Activity Relationship Database with XtalPi Inc., an AI-based pharmaceutical biotechnology company reinventing the industry's approach to drug research and development with its Intelligent Digital Drug Discovery and Development platform. Excelra will provide ADMET datasets in the GOSTAR database to XtalPi Inc. as part of the partnership. GOSTAR's ADMET data will power XtalPi's predictive models. The data helps XtalPi with high precision and predictability to confidently tackle clinical failures of new chemical entities. The well-annotated, high-quality ADMET datasets of GOSTAR are built with a proprietary QMS-ISO certified curation process powered by NLP and human intelligence. GOSTAR provides comprehensive information encompassing over 8 million compounds, manually curated from a variety of sources including patents and journal articles. The database contains over 29 million SAR associated data points. The well-structured relational database can be utilized for diverse applications across various stages of drug discovery and development lifecycle and aids in target validation, hit identification, early lead identification, and optimization. "In XtalPi Inc., we develop advanced AI-based algorithms to tackle the challenges in the drug design process. The size and quality of datasets are always a big concern for us to build high-accuracy predictive models. That is why we consider GOSTAR as a unique and precious resource. It has millions of data points covering different compounds' ADMET properties and is also trustful, structured, and updated. We highly recommend GOSTAR to whoever is involved in the innovation of drug design methodologies." Min Xu, Senior Scientist, Research Manager, XtalPi Inc Norman Azoulay, Product Leader, Excelra, said, "Artificial Intelligence and Machine Learning is bringing a paradigm shift to drug discovery and development. This partnership will help train XtalPi's models to accurately predict efficacy and safety parameters and to ultimately increase the success rate of drug design." About XtalPi XtalPi is a pharmaceutical technology company that is reinventing the industry's approach to drug research and development with its Intelligent Digital Drug Discovery and Development platform. With tightly interwoven quantum physics, artificial intelligence, and high-performance cloud computing algorithms, XtalPi's platform provides accurate predictions on the physiochemical and pharmaceutical properties of small-molecule candidates for drug design, solid-form selection, and other critical aspects of drug development. XtalPi is dedicated to improving the efficiency, accuracy, and success rate of drug research and development, and contributing to a healthier society worldwide. About Excelra Excelra's data and analytics solutions empower innovation in life sciences from molecule to market. The Excelra Edge comes from harmonizing heterogeneous data sets, applying innovative bioinformatics know-how and technologies to accelerate your drug discovery & development with reliable and result-oriented insights. Excelra's GOSTAR is available as an application for users to seek, find, and discover compounds. In addition, it is offered via APIs and as a downloadable dataset to power in-house libraries and machine learning models.

Read More

Judge wipes out Biogen's Tecfidera patent protections in suit against Mylan

Fiercepharma | June 18, 2020

In the high-stakes patent fight between Biogen and Mylan over Tecfidera’s main remaining patent, Mylan has scored a major win in federal court. U.S. District Judge Irene Keeley said Mylan “demonstrated by clear and convincing evidence” that certain claims of Biogen’s '514 patent are invalid for “lack of written description.” The decision threatens Biogen’s bestselling medicine with early generics; Tecfidera, a multiple sclerosis drug, generated $3.3 billion in the U.S. last year. The company's '514 patent is set to expire in 2028, meaning the decision, if upheld, could wipe out years of monopoly sales. Biogen’s shares were down about 6% on Thursday morning on the news. A spokesman said the company is disappointed with the decision and will appeal.

Read More

reVision Therapeutics, Inc. Announces License with Cornell to Develop Treatment for Stargardt Disease

reVision | September 01, 2020

reVision Therapeutics, Inc. ("reVision" or the "Company"), a privately-held, early stage biopharmaceutical company focused on the development and commercialization of innovative therapies for ocular and rare diseases, today announced that it has signed an exclusive license agreement with Cornell University ("Cornell") for the development and commercialization of Cornell's proprietary technology for the treatment of Stargardt disease, a genetic disorder that affects central vision. "The Cornell license represents a significant milestone for reVision and underscores the Company's commitment to innovative therapies and treatments for unmet medical needs associated with genetic and progressive vision loss," said Paul Fehlner, reVision's President and Chief Executive Officer. "We believe this will enable us to accelerate the development of our Stargardt disease treatment, which was the basis for founding reVision. We would like to congratulate the Cornell research team for their superb work in elucidating a novel mechanism of action to treat this devastating disease."

Read More

Spotlight

Modern-day research produces a vast amount of information. The cloud provides a solution for those drowning in this data deluge, and this infographic reviews how cloud-based solutions work and how they can benefit your research.